A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Cedazuridine/decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 15 Oct 2019 Planned number of patients changed from 122 to 160.
- 01 Jul 2019 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
- 01 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2020.